先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量

第一财经09-23 10:23

国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。　　如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。　　2026张江药谷大会暨上海国际生物医药产业周期间，先声药业总裁周云曙接受第一财经记者采访时表示，所谓“卖早了”“卖青苗”，与企业发展...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669017165?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-23 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669017165","market":"sh","top_or_hot":-1,"title":"先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量","media":"第一财经","content":"<div>\n<p>国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。　　如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。　　2026张江药谷大会暨上海国际生物医药产业周期间，先声药业总裁周云曙接受第一财经记者采访时表示，所谓“卖早了”“卖青苗”，与企业发展...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609233882254548.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-23 10:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609233882254548.html><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。　　如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。　　2026张江药谷大会暨上海国际生物医药产业周期间，先声药业总裁周云曙接受第一财经记者采访时表示，所谓“卖早了”“卖青苗”，与企业发展...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609233882254548.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828631.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609233882254548.html","article_id":"2669017165","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882254548.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2669017165","pubTimestamp":1790130233,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK1583":"高瓴概念","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0239":"医药制造","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0183":"MSCI概念","02096":"先声药业","BK0188":"融资融券","BK0012":"证金概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0028":"国家队","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1191":"制药","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0060":"抗癌","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC"},"translate_title":"Zhou Yunshu of Simcere Pharmaceuticals: External authorization is a phased choice, and we will no longer simply pursue quantity in the future.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"02096":1.5},"content_text":"国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。　　如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。　　2026张江药谷大会暨上海国际生物医药产业周期间，先声药业总裁周云曙接受第一财经记者采访时表示，所谓“卖早了”“卖青苗”，与企业发展阶段相适应。如果企业尚不具备海外研发与商业化能力，出让海外权益能够快速获取现金流。加之新药本身存在高度不确定性，能否成功获批、商业远景如何等都难以预判，对外授权成为现实选择。　　2022年后，中国医药行业遭遇资本寒冬，传统的“融资-烧钱-上市”路径难以为继，迫使企业转向产品授权出海、战略合作等方式获取至关重要的研发资金。跨国药企也面临专利悬崖挑战，亟需扩充产品管线，双重因素共振之下，带动了中国创新药对外授权交易热潮。　　国家药监局数据显示，2026年上半年，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。　　今年上半年，先声药业的创新药收入达到38.9亿元，占比达到84.9%。　　对外授权也成为公司推动自主创新成果走向全球的重要路径。近年来，公司也达成6笔对外授权交易，潜在交易总额超61亿美元。　　“公司会更加关注许可交易质量与管线长期价值，不再简单追求交易数量。对外授权有助于已授权产品的海外开发，同时让公司在临床研究、海外注册、商业化统筹能力上得到提升，未来国际化能力将是重点提升的方向。”周云曙说。　　事实上，行业对外授权热潮正在发生结构性变化：合作模式从单一产品授权，逐步转向平台化、更早阶段的全方位协同。　　周云曙表示，公司优化后的对外授权出海策略有几种，一是从单一合作转向更多技术平台型合作；二是不再简单出售早期资产，而是积累更多临床数据后再与跨国巨头合作，参与全球分权与利益共享；三是从单产品、共享型合作出发，推动授权许可成为可持续的增长曲线，而非临时性的第二增长曲线。（文章来源：第一财经）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669017165","isCrawlerRequest":true}